{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:26:36Z","timestamp":1770823596143,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":5368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1038\/modpathol.2008.14","type":"journal-article","created":{"date-parts":[[2008,4,25]],"date-time":"2008-04-25T05:36:08Z","timestamp":1209101768000},"page":"S23-S30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S2","title":["Targeted therapy of cancer: new roles for pathologists in colorectal cancer"],"prefix":"10.1016","volume":"21","author":[{"given":"Stanley R","family":"Hamilton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2008.14_bib1","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.2741\/1410","article-title":"Pharmacogenomics of thymidylate synthase in cancer treatment","volume":"9","author":"Danenberg","year":"2004","journal-title":"Front Biosci"},{"key":"10.1038\/modpathol.2008.14_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","article-title":"Systematic review of microsatellite instability and colorectal cancer prognosis","volume":"23","author":"Popat","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib3","first-page":"38","article-title":"Does biomolecular characterization of stage II\/III colorectal cancer have any prognostic value?","volume":"6","author":"Funaioli","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1038\/modpathol.2008.14_bib4","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/annonc\/mdl029","article-title":"Adjuvant therapy in colon cancer\u2014what, when and how?","volume":"17","author":"Chau","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2008.14_bib5","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1053\/j.seminoncol.2005.04.016","article-title":"Adjuvant chemotherapy of stage III colon cancer","volume":"32","author":"Benson","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib6","first-page":"4809","article-title":"Adjuvant chemotherapy for colon cancer","volume":"26","author":"Pallis","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1038\/modpathol.2008.14_bib7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.11-9-973","article-title":"New approaches to the adjuvant therapy of colon cancer","volume":"11","author":"Benson","year":"2006","journal-title":"Oncologist"},{"key":"10.1038\/modpathol.2008.14_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/14737159.5.3.353","article-title":"Molecular markers that predict response to colon cancer therapy","volume":"5","author":"Ahmed","year":"2005","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1038\/modpathol.2008.14_bib9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/14622416.6.6.603","article-title":"Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer","volume":"6","author":"Allen","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1038\/modpathol.2008.14_bib10","series-title":"New Trends in Cancer for the 21st Century","first-page":"211","article-title":"Pharmacogenomics and colorectal cancer","author":"Lenz","year":"2006"},{"key":"10.1038\/modpathol.2008.14_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/07357900500449637","article-title":"Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer","volume":"24","author":"Holen","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1038\/modpathol.2008.14_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.coph.2006.02.005","article-title":"Predicting the outcome of chemotherapy for colorectal cancer","volume":"6","author":"Allen","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1038\/modpathol.2008.14_bib13","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","article-title":"ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer","volume":"24","author":"Locker","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jcp.20357","article-title":"Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy","volume":"204","author":"Russo","year":"2005","journal-title":"J Cell Physiol"},{"key":"10.1038\/modpathol.2008.14_bib15","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1517\/14656566.7.14.1857","article-title":"Clinical application of pharmacogenetics in gastrointestinal diseases","volume":"7","author":"Saito","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1038\/modpathol.2008.14_bib16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.298.7.754","article-title":"Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer","volume":"298","author":"Meyerhardt","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1038\/modpathol.2008.14_bib17","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2006.06.0863","article-title":"Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803","volume":"24","author":"Meyerhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ctrv.2006.01.002","article-title":"Radiation therapy and combined modality treatment of gastrointestinal carcinomas","volume":"32","author":"Ochler","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/modpathol.2008.14_bib19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000098110","article-title":"Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil","volume":"70","author":"Ciaparrone","year":"2006","journal-title":"Oncology"},{"key":"10.1038\/modpathol.2008.14_bib20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ijc.22318","article-title":"The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil","volume":"120","author":"Jensen","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1038\/modpathol.2008.14_bib21","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.seminoncol.2004.09.027","article-title":"Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer","volume":"32","author":"Grem","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijc.21843","article-title":"Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: Three-gene expression model predicts clinical response","volume":"119","author":"Matsuyama","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1038\/modpathol.2008.14_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098249","article-title":"Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer","volume":"53","author":"Matsusaka","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1038\/modpathol.2008.14_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1615\/CritRevOncog.v12.i1-2.60","article-title":"Methyl-group metabolism and the response of colorectal cancer to 5-fluorouracil","volume":"12","author":"Iacopetta","year":"2006","journal-title":"Crit Rev Oncog"},{"key":"10.1038\/modpathol.2008.14_bib26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10637-005-4021-7","article-title":"Thymidylate synthase pharmacogenetics","volume":"23","author":"Marsh","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1038\/modpathol.2008.14_bib27","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1158\/0008-5472.CAN-06-2165","article-title":"Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy","volume":"66","author":"Brody","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-4020-5133-3_18","article-title":"Pharmacogenomics and colorectal cancer","volume":"587","author":"Lenz","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"10.1038\/modpathol.2008.14_bib29","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/1078-0432.CCR-06-0178","article-title":"Thymidylate synthase expression in colon carcinomas with microsatellite instability","volume":"12","author":"Sinicrope","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib30","first-page":"4653","article-title":"Expression of genes for 5-FU-metabolizing enzymes and response to irinotecan plus 5-FU-leucovorin in colorectal cancer","volume":"26","author":"Noda","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1038\/modpathol.2008.14_bib31","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/annonc\/mdl301","article-title":"A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer","volume":"17","author":"Popat","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1038\/modpathol.2008.14_bib32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2006.05.8172","article-title":"Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute\u2013National Surgical Adjuvant Breast and Bowel Project collaborative study","volume":"25","author":"Kim","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2008.14_bib34","first-page":"1343","article-title":"P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma","volume":"7","author":"Elsaleh","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib35","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1158\/1078-0432.CCR-07-1011","article-title":"Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy","volume":"13","author":"Shen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/07357900500524702","article-title":"Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question","volume":"24","author":"van Kuilenburg","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1038\/modpathol.2008.14_bib37","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00003088-200645060-00002","article-title":"How may anticancer chemotherapy with fluorouracil be individualized?","volume":"45","author":"Ploylearmsaeng","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1038\/modpathol.2008.14_bib38","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1634\/theoncologist.11-9-1003","article-title":"Update on capecitabine in colorectal cancer","volume":"11","author":"Schmoll","year":"2006","journal-title":"Oncologist"},{"key":"10.1038\/modpathol.2008.14_bib39","first-page":"324","article-title":"Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer","volume":"17","author":"Salgado","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1038\/modpathol.2008.14_bib40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00129785-200505010-00002","article-title":"Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer","volume":"5","author":"Lentz","year":"2005","journal-title":"Am J Pharmacogenomics"},{"key":"10.1038\/modpathol.2008.14_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ctrv.2007.07.001","article-title":"Current status of excision repair cross complementing-group 1 (ERCC1) in cancer","volume":"33","author":"Gossage","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/modpathol.2008.14_bib42","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-04-2119","article-title":"FAS\/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer","volume":"11","author":"Nadal","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib43","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjc.6601975","article-title":"A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU\/oxaliplatin combination chemotherapy in refractory colorectal cancer","volume":"91","author":"Stoehlmacher","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1038\/modpathol.2008.14_bib44","first-page":"162","article-title":"ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy","volume":"1","author":"Park","year":"2003","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1038\/modpathol.2008.14_bib45","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-04-2216","article-title":"ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin\/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer","volume":"11","author":"Viguier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2008.14_bib46","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1245\/s10434-006-9112-y","article-title":"Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?","volume":"13","author":"Suh","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1038\/modpathol.2008.14_bib47","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2006.08.1844","article-title":"Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy","volume":"25","author":"Ruzzo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib48","first-page":"637","volume":"17","author":"Martinez-Balibrea","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1038\/modpathol.2008.14_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","article-title":"Irinotecan in the treatment of colorectal cancer","volume":"32","author":"Fuchs","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.1038\/modpathol.2008.14_bib50","doi-asserted-by":"crossref","unstructured":"Bertagnolli MM, Compton CC, Niedzwiecki D, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol 2006;24:abstract 10003.","DOI":"10.1200\/jco.2006.24.18_suppl.10003"},{"key":"10.1038\/modpathol.2008.14_bib51","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/07357900600896281","article-title":"Pharmacogenomics of colorectal cancer prevention and treatment","volume":"24","author":"Nguyen","year":"2006","journal-title":"Cancer Invest"},{"issue":"6 Suppl 9","key":"10.1038\/modpathol.2008.14_bib52","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1053\/j.seminoncol.2005.06.003","article-title":"The role of bevacizumab as first-line therapy for colon cancer","volume":"32","author":"Marshall","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-1-4020-5133-3_20","article-title":"Vascular endothelial growth factor inhibitors in colon cancer","volume":"587","author":"Diaz-Rubio","year":"2006","journal-title":"Adv Exp Med Biol"},{"key":"10.1038\/modpathol.2008.14_bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2005.01.5388","article-title":"Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer","volume":"24","author":"Jubb","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib55","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/dji174","article-title":"Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab","volume":"97","author":"Ince","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/modpathol.2008.14_bib56","first-page":"626","article-title":"Predicting benefit from anti-angiogenic agents in malignancy","volume":"6","author":"Jubb","year":"2006","journal-title":"Nature"},{"key":"10.1038\/modpathol.2008.14_bib57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.cad.0000217425.44584.9f","article-title":"Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer","volume":"17","author":"Hebbar","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1038\/modpathol.2008.14_bib58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1358\/dot.2006.42.11.1032061","article-title":"Panitumumab","volume":"42","author":"Chua","year":"2006","journal-title":"Drugs Today"},{"key":"10.1038\/modpathol.2008.14_bib59","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/14712598.6.11.1229","article-title":"Panitumumab in colon cancer: a review and summary of ongoing trials","volume":"6","author":"Wainberg","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1038\/modpathol.2008.14_bib60","unstructured":"Cappuzzo F, Finocchiaro G, Rossi E, et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 2007, Oct 31; e-pub ahead of print."},{"key":"10.1038\/modpathol.2008.14_bib61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2008.14_bib62","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2007.11.5956","article-title":"Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab","volume":"25","author":"Sartore-Bianchi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib63","doi-asserted-by":"crossref","unstructured":"Italiano A, Follana P, Caroli F-X, et al. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number. Ann Surg Oncol 2007, Nov 7; e-pub ahead of print.","DOI":"10.1245\/s10434-007-9667-2"},{"key":"10.1038\/modpathol.2008.14_bib64","first-page":"1159","article-title":"Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods","volume":"29","author":"Spindler","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1038\/modpathol.2008.14_bib65","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1200\/JCO.2005.09.100","article-title":"Molecular determinants of cetuximab efficacy","volume":"23","author":"Vallbohmer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib66","doi-asserted-by":"crossref","first-page":"168s","DOI":"10.1200\/jco.2007.25.18_suppl.4021","article-title":"EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer","volume":"25","author":"Finocchiaro","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib67","unstructured":"De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2007, Nov 12; e-pub ahead of print."},{"key":"10.1038\/modpathol.2008.14_bib68","first-page":"637","volume":"17","author":"Martinez-Balibrea","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1038\/modpathol.2008.14_bib69","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1200\/JCO.2005.05.2084","article-title":"Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Meropol","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib70","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1200\/JCO.2001.19.23.4298","article-title":"ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy","volume":"19","author":"Shirota","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib71","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1200\/JCO.2005.04.2739","article-title":"Lymph node status and TS gene expression are prognostic markers in stage II\/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy","volume":"24","author":"Liersch","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2008.14_bib72","doi-asserted-by":"crossref","first-page":"168s","DOI":"10.1200\/jco.2007.25.18_suppl.4020","article-title":"How well do we communicate with patients concerning adjuvant systemic therapy? A survey of 150 colorectal cancer survivors","volume":"25","author":"Love","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol200814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol200814","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222023547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222023547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol200814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:58:48Z","timestamp":1760230728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222023547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":72,"alternative-id":["S0893395222023547"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2008.14","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy of cancer: new roles for pathologists in colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2008.14","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2008 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}